The existence of two acute myeloid leukaemia classification systems-one put forth by WHO and one by the International Consensus Classification in 2022-is concerning. Although both systems appropriately move towards genomic disease definitions and reduced emphasis on blast enumeration, there are consequential disagreements between the two systems on what constitutes a diagnosis of acute myeloid leukaemia. This fundamental problem threatens the ability of heath-care providers to diagnose acute myeloid leukaemia, communicate with patients and other health-care providers, and deliver appropriate and consistent management strategies for patients with the condition. Clinical trial eligibility, standardised response assessments, and eventual drug development and regulatory pathways might also be negatively affected by the discrepancies. In this Viewpoint, we review the merits and limitations of both classification systems and illustrate how the coexistence, as well as application of both systems is an undue challenge to patients, clinicians, hematopathologists, sponsors of research, and regulators. Lastly, we emphasise the urgency and propose a roadmap, by which the two divergent classification systems can be harmonised.

Shallis, R.m., Daver, N., Altman, J.k., Komrokji, R.s., Pollyea, D.a., Badar, T., et al. (2023). Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. THE LANCET. HAEMATOLOGY, 10(9), e767-e776 [10.1016/S2352-3026(23)00159-X].

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

Voso M. T.;
2023-09-01

Abstract

The existence of two acute myeloid leukaemia classification systems-one put forth by WHO and one by the International Consensus Classification in 2022-is concerning. Although both systems appropriately move towards genomic disease definitions and reduced emphasis on blast enumeration, there are consequential disagreements between the two systems on what constitutes a diagnosis of acute myeloid leukaemia. This fundamental problem threatens the ability of heath-care providers to diagnose acute myeloid leukaemia, communicate with patients and other health-care providers, and deliver appropriate and consistent management strategies for patients with the condition. Clinical trial eligibility, standardised response assessments, and eventual drug development and regulatory pathways might also be negatively affected by the discrepancies. In this Viewpoint, we review the merits and limitations of both classification systems and illustrate how the coexistence, as well as application of both systems is an undue challenge to patients, clinicians, hematopathologists, sponsors of research, and regulators. Lastly, we emphasise the urgency and propose a roadmap, by which the two divergent classification systems can be harmonised.
set-2023
Online ahead of print
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/15
English
Shallis, R.m., Daver, N., Altman, J.k., Komrokji, R.s., Pollyea, D.a., Badar, T., et al. (2023). Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. THE LANCET. HAEMATOLOGY, 10(9), e767-e776 [10.1016/S2352-3026(23)00159-X].
Shallis, Rm; Daver, N; Altman, Jk; Komrokji, Rs; Pollyea, Da; Badar, T; Bewersdorf, Jp; Bhatt, Vr; de Botton, S; de la Fuente Burguera, A; Carraway, H...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/379930
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact